My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AbbVie (NY:ABBV)

234.00 +1.64 (+0.71%)

Official Closing Price Updated: 7:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

89 90 Next >

Is Eli Lilly a Buy? Analyst Confidence Grows for 2025

November 05, 2024

Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. New highs are likely by early 2025.

Via MarketBeat

Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings

November 05, 2024

After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors.

Via MarketBeat

Topics Intellectual Property

Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today ↗

November 04, 2024

Via Benzinga

High-Yield AbbVie Gains Momentum: A 20% Upside Is in Sight

November 04, 2024

High-yielding AbbVie is on track for another 20% gain, which could happen by the end of the year. Analysts are raising their targets, leading to higher prices.

Via MarketBeat

Topics Intellectual Property

AbbVie Dividend Increase ↗

November 03, 2024

On 30 October, AbbVie (ABBV) increased its quarterly dividend by 5.81%, from $1.55 to $1.64 per share.

Via Talk Markets

Price Over Earnings Overview: AbbVie ↗

November 01, 2024

Via Benzinga

Market Analysis: AbbVie And Competitors In Biotechnology Industry ↗

October 31, 2024

Via Benzinga

AbbVie's Options Frenzy: What You Need to Know ↗

October 30, 2024

Via Benzinga

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade ↗

November 01, 2024

On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79.

Via Investor's Business Daily

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗

November 01, 2024

The major indexes declined, but haven't fallen apart.

Via Investor's Business Daily

5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs ↗

October 31, 2024

It's hard to beat the power of dividend-paying stocks. They have outperformed non-payers significantly.

Via The Motley Fool

Forecasting The Future: 11 Analyst Projections For AbbVie ↗

October 25, 2024

Via Benzinga

Check Out What Whales Are Doing With ABBV ↗

October 24, 2024

Via Benzinga

AbbVie’s Dividend Isn’t As Scary As It Looks ↗

October 30, 2024

AbbVie currently pays shareholders a quarterly dividend of $1.55 per share, which gives the stock a 3.3% yield on the current price.

Via Talk Markets

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗

October 30, 2024

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.

Via Benzinga

Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday? ↗

October 30, 2024

Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data.

Via Benzinga

AbbVie (ABBV) Q3 2024 Earnings Call Transcript ↗

October 30, 2024

ABBV earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth ↗

October 30, 2024

AbbVie's Q3 earnings surpassed expectations with $3.00 EPS and $14.46 billion in revenue. Skyrizi and Rinvoq led growth; AbbVie also raised 2024 EPS guidance.

Via Benzinga

AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat ↗

October 30, 2024

AbbVie easily beat third-quarter expectations and raised its earnings outlook for the year.

Via Investor's Business Daily

3 Dividend Growth Stocks to Buy and Never Sell ↗

October 30, 2024

These 3 dividend growth stocks have crushed the market and show no signs of slowing down.

Via The Motley Fool

Biotech Momentum Trades For The Q4 Rally ↗

October 29, 2024

The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.

Via Talk Markets

AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings ↗

October 29, 2024

AbbVie (ABBV) reports Q3 earnings Wednesday. The acquisition of Aliada Therapeutics may boost its Alzheimer's portfolio and stock, currently up 33.68% YTD.

Via Benzinga

Sweetgreen, Tesla, Digital Realty Trust And A Health Care Stock On CNBC's 'Final Trades' ↗

October 28, 2024

Sweetgreen shares closed at $37.48 during Friday's session. Analysts also discuss Tesla, AbbVie and Digital Realty Trust on 'Final Trades'

Via Benzinga

What Lies In Store For Healthcare ETFs In Q3 Earnings? ↗

October 27, 2024

The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.

Via Talk Markets

Topics ETFs

3 Dividend Growth Stocks You Can Buy and Hold Forever ↗

October 26, 2024

These healthcare stocks have fantastic dividend track records.

Via The Motley Fool

3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees ↗

October 25, 2024

These stocks yield between 2.8% and 3.3% in dividends.

Via The Motley Fool

Beat the Nasdaq With This Cash-Gushing Dividend Stock ↗

October 23, 2024

The company is performing well despite recently losing its biggest growth driver.

Via The Motley Fool

3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime ↗

October 23, 2024

These three Vanguard ETFs are worth considering for the long term.

Via The Motley Fool

Topics ETFs

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

3 Growth Stocks That Could Be Bargain Buys Right Now ↗

October 18, 2024

These stocks trade at less than 20 times their estimated future profits.

Via The Motley Fool

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

89 90 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.